Physician profile
Ronald Ralph
NPI 1467412916
$7,546.75
in general payments reported to CMS, 2019-2025
46 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $798 · 2020: $676 · 2021: $963 · 2022: $1,231 · 2023: $1,115 · 2024: $1,319 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,879.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,879.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $890.54 | 2019-2025 | Farxiga, Evusheld, Lokelma |
| Mallinckrodt Hospital Products INC. | $845.12 | 2020-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $685.13 | 2022-2025 | |
| Horizon Therapeutics Plc | $563.72 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $561.46 | 2021-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $505.06 | 2019-2025 | Jynarque, Voyxact |
| Vifor Pharma, INC. | $351.95 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $332.90 | 2021-2025 | |
| Amgen INC. | $307.80 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Mallinckrodt Enterprises LLC | $250.88 | 2019 | |
| Lilly USA, LLC | $192.12 | 2023-2025 | Jardiance, Zepbound, Emgality |
| Abbvie INC. | $178.98 | 2022-2025 | |
| Medtronic, INC. | $173.84 | 2023 | Ellipsys Vascular Access System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $173.26 | 2023-2025 | Jardiance |
| Abbott Laboratories | $170.42 | 2024 | Cardiomems |
Show all 40 companies
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Ralph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.